#### AI in Healthcare

-

IBM Watson Health
Brenda Segaria
Pre-Sales Consultant IBM Watson Health Imaging

Jennifer Mele Client Executive Provider Sales




IBM's statements regarding its plans, directions and intent are subject to change or withdrawal without notice at IBM's sole discretion.

Information regarding potential future products is intended to outline our general product direction and it should not be relied on in making a purchasing decision.

The information mentioned regarding potential future products is not a commitment, promise, or legal obligation to deliver any material, code or functionality. Information about potential future products may not be incorporated into any contract. The development, release, and timing of any future features or functionality described for our products remains at our sole discretion.

#### Today's presenters



**Brenda Segaria**Pre-Sales Consultant
Watson Health Imaging



Jennifer Mele
Client Executive
Watson Health Provider Sales

We bring the power of artificial intelligence to healthcare to expand the physician's view so they have greater confidence in their diagnostic and treatment decisions for their patients



#### The power of Watson

Human + Machine = greater than the sum of its parts

#### Humans excel at:







**Dilemmas** 



Morals



Compassion



**Imagination** 



Dreaming



Abstraction



Generalization

#### AI systems excel at:



Natural Language



Pattern Identification



Locating Knowledge



Machine Learning



Eliminate Bias



**Endless** Capacity

## Imagine AI for medicine that aspires to

See expansively

Reads structured and unstructured data

Recognize more reliably

Identifies contextually-relevant data

Communicate more objectively

Presents users with evidence-based findings

#### Al at IBM



## Capabilities



Cloud



Content



Cognitive Computing



Collaboration

200M+
claims
TRUVEN
HEALTH ANALYTICS

100M+
patient
records
o explorys
An IBM Company

Billions
images
managed
MERGE

1.2M medical abstracts

3B+
reference
points

4M+ drug patents

40M+ research documents

## The IBM Watson Imaging AI Portfolio



**Patient Synopsis** 





#### Data in EMR systems are often...




which can delay or distort care decisions

Data discrepancies existing in today's documentation can be harmful at both the patient and system level

There is a need to correctly report data at the patient level to optimize the broader healthcare system




Watson Imaging Clinical Review is a retrospective cognitive data review tool that helps support a reliable patient record in order to drive accurate, timely, and coordinated care decisions




Radiologists play a crucial, consultative role within the patient care team. Communication difficulties and information disparities, increasingly high output expectations, and numerous distractions throughout each day present growing challenges to this already complex role.

IBM sponsored voice of customer study

Watson Imaging Patient Synopsis is a radiologist-trained AI tool that **efficiently informs care decisions** made by clinicians. It extracts relevant patient information from the EHR and projects it via a single-view summary screen in sync with PACS... in seconds.



Watson Oncology Suite leverages AI to harness insights from cancer guidelines, literature, treatment options, clinical trials and patient records while integrating with existing work flows. It helps doctors and patients make better-informed, evidence based treatment decisions and identifies more patients for more trials in less time.



# Let us tell you more...

Brenda.Segaria@ibm.com

Jennifer.Mele@ibm.com

#### Legal Disclaimer

© IBM Corporation 2018. All Rights Reserved.

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on IBM's current product plans and strategy, which are subject to change by IBM without notice. IBM shall not be responsible for any damages arising out of the use of, or otherwise related to, this publication or any other materials. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from IBM or its suppliers or licensors, or altering the terms and conditions of the applicable license agreement governing the use of IBM software.

References in this presentation to IBM products, programs, or services do not imply that they will be available in all countries in which IBM operates. Product release dates and/or capabilities referenced in this presentation may change at any time at IBM's sole discretion based on market opportunities or other factors, and are not intended to be a commitment to future product or feature availability in any way. Nothing contained in these materials is intended to, nor shall have the effect of, stating or implying that any activities undertaken by you will result in any specific sales, revenue growth or other results.

Performance is based on measurements and projections using standard IBM benchmarks in a controlled environment. The actual throughput or performance that any user will experience will vary depending upon many factors, including considerations such as the amount of multiprogramming in the user's job stream, the I/O configuration, the storage configuration, and the workload processed. Therefore, no assurance can be given that an individual user will achieve results similar to those stated here.

All customer examples described are presented as illustrations of how those customers have used IBM products and the results they may have achieved. Actual environmental costs and performance characteristics may vary by customer.

IBM, the IBM logo, ibm.com, and Watson Health are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. Other product and service names might be trademarks of IBM or other companies. A current list of IBM trademarks is available on the Web at "Copyright and trademark information" at ibm.com/legal/copytrade.

#### Forward Looking Statements

Certain statements contained in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the company's current assumptions regarding future business and financial performance. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including the following: a downturn in the economic environment and client spending budgets; the company's failure to meet growth and productivity objectives; a failure of the company's innovation initiatives; risks from investing in growth opportunities; failure of the company's intellectual property portfolio to prevent competitive offerings and the failure of the company to obtain necessary licenses; cybersecurity and data privacy considerations; fluctuations in financial results; impact of local legal, economic, political and health conditions; adverse effects from environmental matters, tax matters and the company's pension plans; ineffective internal controls; the company's use of accounting estimates; the company's ability to attract and retain key personnel and its reliance on critical skills; impacts of relationships with critical suppliers; product quality issues; impacts of business with government clients; currency fluctuations and customer financing risks; impact of changes in market liquidity conditions and customer credit risk on receivables; reliance on third party distribution channels and ecosystems; the company's ability to successfully manage acquisitions, alliances and dispositions; risks from legal proceedings; risk factors related to IBM securities; and other risks, uncertainties and factors discussed in the company's Form 10-Qs, Form 10-K and in the company's other filings with the U.S. Securities and Exchange Commission (SEC) or in materials incorporated therein by reference. The company assumes no obligation to update or revise any forward-looking statements. These charts and the associated remarks and comments are integrally related, and are intended to be presented and understood together.

